Regulatory Governance of Emerging Health Technologies
4 Dec (Mon) – 6 Dec (Wed)
11/F, Cheng Yu Tung Tower, Centennial Campus, HKU or ZOOM
Prior registration is required.
All are welcome.
*Simultaneous interpretation in English & Mandarin on 4-6 Dec
With support from the Medical Ethics & Humanities Unit (Faculty of Medicine), the Centre for Medical Ethics and Law is delighted to present an international conference that seeks to examine:
(1) What is the “regulatory state” vis-à-vis biomedical R&D, who are the key actors and what are their roles?
(2) What is law in the “regulatory state” and what is its contribution to this phenomenon and to biomedical R&D?
(3) What is bioethical in the “regulatory state” and what is its contribution to this phenomenon and to biomedical R&D?
(4) To what extent are the goals of (2) consistent with those of (3)? How are conflicts (if any) resolved?
(5) What are the normative implications of the rise of the “regulatory state” on global governance of biomedical R&D?
Recent advances in genetics and human reproductive technologies continue to present distinctive ethical and legal challenges. For instance, advances in high-throughput sequencing technologies have enabled the detection of chromosomal abnormalities in a foetus through non-invasive prenatal testing (or NIPT). Expanded testing conducted in NIPT has further raised concerns as to whether a child’s right to an open future requires parental freedoms to be curtailed. In a research context, it is as yet unclear whether and when actionable genomic results in a research biobank should be returned to an individual or otherwise shared with third parties who could potentially benefit from having access to these results. In this international conference, leading scholars examine the nature and implications of the regulatory governance of emerging genetic and reproductive technologies, as well as the rise of the regulatory state in promoting biomedical research and development (R&D) through the use of direct and indirect rules, and in the variety of regulatory regimes involving non-state actors (e.g. private regulation, self-regulation and civil regulation) that have emerged.
Advances in Genomics;
Access to Novel Technologies
Dr Calvin W.L. Ho &
Prof Gilberto K.K. Leung
Centre for Medical Ethics and Law, Faculties of Law & Medicine, The University of Hong Kong
“Advances in Genomics”
Day 1 Afternoon Session
4 Dec (Mon) 14:30-18:15 (HKT)
Dr Katherine Littler World Health Organization, Geneva
Prof Xiaomei Zhai Tsinghua University
Prof Kathleen Liddell University of Cambridge
Prof Mateo Aboy University of Cambridge
Prof Yann Joly McGill University
Dr Colin Mitchell University of Cambridge
Ms Momoko Sato RIKEN, Japan
Day 2 Morning Session
5 Dec (Tue) 10:00-12:30 (HKT)
Prof Jane Kaye University of Oxford
Dr Derrick Au Chinese University of Hong Kong & Hong Kong Genome Institute
Dr Matilda Haas Australian Genomics, Melbourne
Dr Chih-Hsing Ho Academia Sinica
Day 2 Afternoon Session
5 Dec (Tue) 14:00-19:00 (HKT)
Dr Catherine Mills Monash University, Melbourne
Prof Fr. Joseph Tham, LC Regina Apostolorum Pontifical University, Italy
Prof Ainsley Newson University of Sydney
Prof Sir Jonathan Montgomery University College London
Dr Sarah Chan University of Edinburgh
Prof Peter Mills University of Cambridge
Prof Sara J Fovargue Sheffield Law School
Prof Yonghui Ma Xiamen University
“Access to Novel Technologies”
Day 3 Morning Session
6 Dec (Wed) 09:30-13:00 (HKT)
Prof Kaori Muto University of Tokyo
Dr Olivia Ngan The University of Hong Kong
Dr Caitlyn A Tabor Harvard Medical School
Ms Tanya Brigden University of Cambridge
Dr Barry Solaiman Hamad Bin Khalifa University
Centre for Medical Ethics and Law (CMEL), The University of Hong Kong
Medical Ethics and Humanities Unit, The University of Hong Kong